Review
doi: 10.2217/nnm.13.68.
Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines
Affiliations
- PMID: 23656268
- DOI: 10.2217/nnm.13.68
Item in Clipboard
Review
Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines
Nanomedicine (Lond).
2013 May.
Abstract
Over the last three decades many first-generation nanomedicines have successfully entered routine clinical use and it is now important for medicines regulatory agencies to consider the mechanisms needed to ensure safe introduction of 'follow-on' nanomedicine products, 'nanosimilars'. Moreover, drug regulators need to ensure that 'next'-generation nanomedicines enter clinical development and consequently the market in a safe and timely way for the benefit of public health. Here we review recent European Medicines Agency activities that relate to the effective development and evaluation of nanomedicine products while keeping patient and consumer safety at the forefront.
Similar articles
-
Regulation of nanomedicines in the EU: distilling lessons from the pediatric and the advanced therapy medicinal products approaches.Nanomedicine (Lond). 2010 Jan;5(1):135-42. doi: 10.2217/nnm.09.91. Nanomedicine (Lond). 2010. PMID: 20025470
-
Nanomedicines and Nanosimilars: Looking for a New and Dynamic Regulatory "Astrolabe" Inspired System.AAPS PharmSciTech. 2020 Jan 13;21(2):65. doi: 10.1208/s12249-019-1573-y. AAPS PharmSciTech. 2020. PMID: 31933006 Review.
-
Nanomedicines: The magic bullets reaching their target?Eur J Pharm Sci. 2019 Feb 1;128:73-80. doi: 10.1016/j.ejps.2018.11.019. Epub 2018 Nov 20. Eur J Pharm Sci. 2019. PMID: 30465818 Review.
-
Nanomedicines: addressing the scientific and regulatory gap.Ann N Y Acad Sci. 2014 Apr;1313:35-56. doi: 10.1111/nyas.12403. Epub 2014 Mar 27. Ann N Y Acad Sci. 2014. PMID: 24673240
-
Regulatory aspects on nanomedicines.Biochem Biophys Res Commun. 2015 Dec 18;468(3):504-10. doi: 10.1016/j.bbrc.2015.08.023. Epub 2015 Aug 8. Biochem Biophys Res Commun. 2015. PMID: 26260323 Review.
Cited by
-
Nanotherapeutics in the EU: an overview on current state and future directions.Int J Nanomedicine. 2014 Feb 19;9:1005-23. doi: 10.2147/IJN.S55359. eCollection 2014. Int J Nanomedicine. 2014. PMID: 24600222 Free PMC article. Review.
-
The Induction of Oxidative/Nitrosative Stress, Inflammation, and Apoptosis by a Ferric Carboxymaltose Copy Compared to Iron Sucrose in a Non-Clinical Model.J Clin Diagn Res. 2015 Dec;9(12):FF08-12. doi: 10.7860/JCDR/2015/14266.6992. Epub 2015 Dec 1. J Clin Diagn Res. 2015. PMID: 26816915 Free PMC article.
-
Nanomedicines and Nanosimilars-Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety.Front Pharmacol. 2022 Feb 24;12:787239. doi: 10.3389/fphar.2021.787239. eCollection 2021. Front Pharmacol. 2022. PMID: 35280250 Free PMC article. No abstract available.
-
Commercial utilities and future perspective of nanomedicines.PeerJ. 2021 Nov 19;9:e12392. doi: 10.7717/peerj.12392. eCollection 2021. PeerJ. 2021. PMID: 34820175 Free PMC article.
-
Future perspectives for advancing regulatory science of nanotechnology-enabled health products.Drug Deliv Transl Res. 2022 Sep;12(9):2145-2156. doi: 10.1007/s13346-022-01165-y. Epub 2022 Jun 12. Drug Deliv Transl Res. 2022. PMID: 35691982 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
